蒽环类药物心脏毒性防治指南(2013年版)
蒽环类药物心脏毒性防治指南(2013年版)
作者：中国临床肿瘤学会， 中华医学会血液学分会
作者单位：
刊名：
临床肿瘤学杂志
英文刊名：Chinese Clinical Oncology
年，卷(期)：2013,18(10)
参考文献(37条)
1.Cvetkovi'c RS;Scott LJ Dexrazoxane:a review of its use for cardioprotection during anthracycline chemotherapy 2005(07)
2.Barry E;Alvarez JA;Scully RE Anthracycline-induced cardiotoxicity:course,pathophysiology,prevention and management 2007(08)
3.Lipshultz SE;Lipsitz SR;Sallan SE Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia 2005(12)
4.Lipshultz SE;Colan SD;Gelber RD Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood 1991(12)
5.Von Hoff DD;Layard MW;Basa P Risk factors for doxorubicin-induced congestive heart failure 1979(05)
6.Swain SM;Whaley FS;Ewer MS Congestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trials 2003(11)
7.Keefe DL Anthracycline-induced cardiomyopathy 2001(4 Suppl 12)
8.Ganame J;Claus P;Uyttebroeck A Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients 2007(12)
9.姜龙;龙浩蒽环类抗肿瘤药物的心脏毒性及保护剂的研究进展[期刊论文]-中国肿瘤临床 2011(16)
10.Robert J;Morvan VL;Smith D Predicting drug response and toxicity based on gene polymorphisms 2005(03)
11.Lipshultz SE;Rifai N;Sallan SE Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury 1997(08)
12.Minotti G;Menna P;Salvatorelli E Anthracyclines:molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity 2004(02)
13.胡莎;贾苍松蒽环类抗肿瘤药物的心脏毒性[期刊论文]-中国小儿血液与肿瘤杂志 2009(02)
14.Simunek T;stérba M;Popelov á O Anthracycline-induced cardiotoxicity:Overview of studies examining the roles of oxidative stress and free cellular iron 2009(01)
15.Hershko C;Pinson A;Link G Prevention of anthracycline cardiotoxicity by iron chelation 1996(01)
16.Ito H;Miller SC;Billingham ME Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro 1990(11)
17.Wallace KB Doxorubicin-induced cardiac mitochondrionopathy 2003(03)
18.Lebrecht D;Setzer B;Ketelsen UP Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy 2003(19)
19.Lebrecht D;Kokkori A;Ketelsen UP Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin 2005(04)
20.Seidman A;Hudis C;Pierri MK Cardiac dysfunction in the trastuzumab clinical trials experience 2002
21.Venturini M;Michelotti A;Mastro LD Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer 1996(12)
22.Marty M;Espie' M;Llombart A Multicenter randomized phase Ⅲ study of the cardioprotective effect of dexrazoxane (Cardioxane_) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy 2006(04)
23.Berry GJ;Jorden M Pathology of radiation and anthracycline cardiotoxicity.Pediatr 2005(07)
24.Barrett-Lee PJ;Dixon JM;Farrell C Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk 2009(05)
25.Marchandise B;Schroeder E;Bosly A Early detection of doxorubicin cardiotoxicity:interest of Doppler echocardiographic analysis of left ventricular filling dynamics 1989(01)
26.Nousiainen T;Jantunen E;Vanninen E Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma 1999(02)
27.Meinardi MT;van Veldhuisen D J;Gietema JA Prospective evaluation of early cardiac damage induced by epirubicincontaining adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients 2001(10)
28.Bovelli D;Plataniotis G;Roila F Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease:ESMO Clinical Practice Guidelines 2010(Suppl 5)
29.van Dalen EC;Caron HN;Dickinson HO Cardioprotective interventions for cancer patients receiving anthracyclines 2011(02)
30.Zhang JN;Zhao Y;Zhao DL Scavenging-effects of dexrazoxane on free radicals 2010(03)
31.Lipshultz SE;Rifai N;Dalton VM The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia 2004(12)
32.曾令源;李晓昕;付彬玉注射用右丙亚胺对阿霉素引起的心脏毒性的保护作用[期刊论文]-药学与临床研究 2008(06)
33.高向阳;韩正祥;杜秀平右丙亚胺对表柔比星所致心脏毒性防治作用的观察[期刊论文]-中华肿瘤防治杂志 2010(04)
34.吴晖;欧阳取长右丙亚胺对乳腺癌术后蒽环类药物化疗所致心脏毒性保护作用的研究[期刊论文]-中国现代医学杂志 2010(14)
35.Choi HS;Park ES;Kang HJ Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors 2010(09)
36.Lipshultz SE;Giantris AL;Lipsitz SR Doxorubicin administration by continuous infusion is not
cardioprotective:the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol 2002(06)
37.Gabizon A;Martin F Polyethylene glycol-coated (pegylated) liposomal doxorubicin.Rationale for use in solid tumours 1997(Suppl 4)
本文链接：https://www.wendangku.net/doc/8a13908092.html,/Periodical_lczlxzz201310014.aspx